A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

NCT04194944 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

261

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Selpercatinib
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Pemetrexed
DRUG: Pembrolizumab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]